An interventional study of Care Coordination and Individual Peer Support in Psychosis, Schizophrenia and Schizoaffective Disorder, sponsored by Mclean Hospital. Recruiting at 5 sites in United States. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Mclean Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Psychotic Disorders by Mclean Hospital — 6 open to participants now, 6 under way, none of them phase 3. Psychotic Disorders · Mclean Hospital.
Among the 18 studies in Psychotic Disorders by Mclean Hospital, this one has the largest planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2024, is one of 11 with no phase, and was the 14th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →6 of the 18 studies in Psychotic Disorders by Mclean Hospital are open now, in 1 country. Recruiting first, the newest first:
Mclean Hospital · Sites in United States
Ages 18–55
Mclean Hospital · Sites in United States
Ages 18–45
Mclean Hospital · Sites in United States
Ages 18–55
Mclean Hospital · Sites in United States
Ages 18–45
Mclean Hospital · Sites in United States
Ages 18–50
By country, each count listing its studies:
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 50 across the 17 interventional studies, 187 across the 1 observational. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mclean Hospital is the lead sponsor of 185 studies on the registry; 31 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 12 (80%) have results posted.
3 of the studies in Psychotic Disorders by Mclean Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07503093Mclean HospitalPilot Study of Sensor-Informed Smartphone-based Mental Health Interventions for Mood in Early Psychosis | 2027-05-01 |
| NCT06558201Mclean HospitalOpen Label Extension Study of NCT06221852 | 2027-09-30 |
| NCT06221852Mclean HospitalKetogenic and Nutritional Interventions for First Episode Bipolar Disorder | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Psychotic Disorders by Mclean Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare engagement in treatment in coordinated specialty care (CSC) to five extra care elements (CSC 2.0) in first-episode psychosis. The main question it aims to answer is:
Participants will either:
Receive care as usual (CSC) plus five additional care elements (CSC 2.0):
Researchers will compare the standard of care (CSC) to CSC 2.0 to see if participants receiving CSC 2.0 have more visits to their clinic in their first year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Care as usual; no intervention.
CSC 2.0 arm will be offered 1:1 peer support, digital outreach, care coordination, multi-family group therapy, and cognitive remediation (if applicable).
Behavioral: Care Coordination · Behavioral: Individual Peer Support · Behavioral: Digital Outreach · Behavioral: Cognitive Remediation · Behavioral: Multi-Family Group Therapy
* The study staff clinician will review all medical issues for each patient and reach out to primary care providers (PCP), dieticians, and other medical providers as needed. * The study staff clinician will serve as point person for communication with emergency departments and inpatient providers if the patient requires those levels of care. * The clinician will communicate with outside providers to provide background and ensure health decision making by those providers, visit and support patients as appropriate, access outside records and share with rest of the care team, and most critically ensure that a proper discharge plan has been made for the patient including care appointments, access to prescriptions and any new referrals made during hospitalization.
• Patients will be offered weekly 1:1 sessions with a Peer Provider as part of routine care in a mixture of in-person and virtual formats as appropriate to support patients around treatment decisions, and recovery.
• mindLAMP smartphone application for various kinds of outreach including but not limited to medication and/or appointment reminders, resources, and activities such as breathing and meditation exercises.
* For participants identified as needing and/or wanting support around cognition. * The cognitive remediation program is available online or in-app and offers memory, attention, processing speed, executive functioning, and social cognition training activities.
* Families whose loved ones are in CSC clinic will be offered weekly group sessions with a study staff clinician. * Each group may include 5-8 families and include a mixture of in-person and virtual formats. * These groups will be open-ended, including psychoeducation, and practical problem-solving discussions around care and other topics.
Months Engaged in Care
Number of months each participant had ≥4 visits in a 12-month period
Time frame: 12 months following clinic intake
Clinic Visit Number
Total number of clinic visits in a 12-month period
Time frame: 12 months following clinic intake
Clinic Visit Type
Numbers of different types of visits (eer provider, psychotherapy, psychopharmacology, group therapy, etc.) in a 12-month period
Time frame: 12 months following clinic intake
Duration of Treatment
Duration of time in treatment
Time frame: Up to 12 months - measured as time between clinic intake and detachment
Proportion in Arm Still in Clinic
Proportion of patients in each arm who are still in CSC at the end of the 12-month follow-up period
Time frame: 12 months following clinic intake
Exploratory Analysis of symptom and functioning measures in EPINET Core Assessment Battery (CAB)
Exploratory analysis of variables collected by EPINET CAB by arm
Time frame: 12 months following clinic intake
Proportion of Early Detachment
Proportion of patients in each arm who detach from clinic prior to the end of their first month in care
Time frame: 1 month
Months Engaged in Care - extension of primary outcome
Number of months each participant had ≥4 visits in a 24-month period
Time frame: 24 months
Started Feb 2024 (actual). Primary completion is estimated for Oct 2028, 56 months after the start.
Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 56 months is above that.
Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.